2,719
Views
32
CrossRef citations to date
0
Altmetric
Addendum

Huntington's disease is a multi-system disorder

Article: e1058464 | Received 14 Apr 2015, Accepted 29 May 2015, Published online: 24 Jul 2015

References

  • Zielonka D, Mielcarek M, Landwehrmeyer GB. Update on Huntington's disease: advances in care and emerging therapeutic options. Parkinsonism Relat Disord 2015; 21:169-178; PMID:25572500; http://dx.doi.org/10.1016/j.parkreldis.2014.12.013
  • Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 1999; 19:2522-2534; PMID:10087066
  • Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz KW, Collins FS, Albin RL. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 1993; 5:259-265; PMID:8275091; http://dx.doi.org/10.1038/ng1193-259
  • Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 2003; 28:425-433; PMID:12932731; http://dx.doi.org/10.1016/S0968-0004(03)00168-3
  • Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995; 11:155-163; PMID:7550343; http://dx.doi.org/10.1038/ng1095-155
  • Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A 2013; 110:2366-2370; PMID:23341618; http://dx.doi.org/10.1073/pnas.1221891110
  • Zielonka D, Piotrowska I, Marcinkowski JT, Mielcarek M. Skeletal muscle pathology in Huntington's disease. Front Physiol 2014; 5:380; PMID:25339908; http://dx.doi.org/10.3389/fphys.2014.00380
  • Zielonka D, Piotrowska I, Mielcarek M. Cardiac dysfunction in Huntington's Disease. Exp Clin Cardiol 2014; 20:2547-2554
  • Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 2008; 117: 2743-2751; PMID:18490523; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.750232
  • Melkani GC, Trujillo AS, Ramos R, Bodmer R, Bernstein SI, Ocorr K. Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart. PLoS Genet 2013; 9:e1004024; PMID; http://dx.doi.org/10.1371/journal.pgen.1004024
  • Mielcarek M, Inuabasi L, Bondulich MK, Muller T, Osborne GF, Franklin SA, Smith DL, Neueder A, Rosinski J, Rattray I, et al. Dysfunction of the CNS-heart axis in mouse models of Huntington's disease. PLoS Genet 2014; 10:e1004550; PMID:25101683; http://dx.doi.org/10.1371/journal.pgen.1004550
  • Mielcarek M, Bondulich MK, Inuabasi L, Franklin SA, Muller T, Bates GP. The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model. PLoS One 2014; 9:e108961; PMID:25268775; http://dx.doi.org/10.1371/journal.pone.0108961
  • Mielcarek M, Toczek M, Smeets CJ, Franklin SA, Bondulich MK, Jolinon N, Muller T, Ahmed M, Dick JR, Piotrowska I, et al. HDAC4-Myogenin Axis As an Important Marker of HD-Related Skeletal Muscle Atrophy. PLoS Genet 2015; 11:e1005021; PMID:25748626; http://dx.doi.org/10.1371/journal.pgen.1005021
  • Mielcarek M, Zielonka D, Carnemolla A, Marcinkowski JT, Guidez F. HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. Front Cell Neurosci 2015; 9:42; PMID:25759639; http://dx.doi.org/10.3389/fncel.2015.00042
  • Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, Bassel-Duby R, Sanes JR, Olson EN. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009; 326:1549-1554; PMID:20007902; http://dx.doi.org/10.1126/science.1181046
  • Bruneteau G, Simonet T, Bauche S, Mandjee N, Malfatti E, Girard E, Tanguy ML, Behin A, Khiami F, Sariali E, et al. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. Brain 2013; 136:2359-2368; PMID:23824486; http://dx.doi.org/10.1093/brain/awt164
  • Bricceno KV, Sampognaro PJ, Van Meerbeke JP, Sumner CJ, Fischbeck KH, Burnett BG. Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice. Hum Mol Genet 2012; 21:4448-4459; PMID:22798624; http://dx.doi.org/10.1093/hmg/dds286
  • Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Osborne GF, Wadel K, Touller C, Butler R, et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol 2013; 11:e1001717; PMID:24302884; http://dx.doi.org/10.1371/journal.pbio.1001717
  • Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One 2011; 6:e27746; PMID:22140466; http://dx.doi.org/10.1371/journal.pone.0027746
  • Fujimoto M, Takaki E, Hayashi T, Kitaura Y, Tanaka Y, Inouye S, Nakai A. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem 2005; 280:34908-34916; PMID:16051598; http://dx.doi.org/10.1074/jbc.M506288200